181 related articles for article (PubMed ID: 29453962)
1. An Autoantibody Against Human DNA-Topoisomerase I Is a Novel Biomarker for Non-Small Cell Lung Cancer.
Wu WB; Yie SM; Ye SR; Xie K; Zhang JB; Cao M; Chen J; He X; Ma XL; Zhang J
Ann Thorac Surg; 2018 Jun; 105(6):1664-1670. PubMed ID: 29453962
[TBL] [Abstract][Full Text] [Related]
2. Serum anti-TOPO48 autoantibody as a biomarker for early diagnosis and prognosis in patients with esophageal squamous cell carcinoma.
Zhang JB; Cao M; Chen J; Ye SR; Xie K; He X; Ma XL; Zhang J; Yie SM
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):276-284. PubMed ID: 29170084
[TBL] [Abstract][Full Text] [Related]
3. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
Fan J; Yu H; Lv Y; Yin L
Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic value of serum Cripto-1 in patients with non-small cell lung cancer.
Xu CH; Chi CZ; Zhang Q; Wang YC; Wang W; Yuan Q; Zhan P; Zhang XW; Lin Y
Clin Respir J; 2018 Oct; 12(10):2469-2474. PubMed ID: 29570945
[TBL] [Abstract][Full Text] [Related]
6. Serum Cripto-1 is a novel biomarker for non-small cell lung cancer diagnosis and prognosis.
Xu CH; Wang Y; Qian LH; Yu LK; Zhang XW; Wang QB
Clin Respir J; 2017 Nov; 11(6):765-771. PubMed ID: 26605871
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic value of serum periostin in patients with non-small cell lung cancer.
Xu CH; Wang W; Lin Y; Qian LH; Zhang XW; Wang QB; Yu LK
Oncotarget; 2017 Mar; 8(12):18746-18753. PubMed ID: 27816968
[TBL] [Abstract][Full Text] [Related]
8. [Clinical significance and diagnostic value of Survivin autoantibody in non-small cell lung cancer patients].
Ma L; Yue W; Zhang L; Wang Y; Zhang C; Yang X
Zhongguo Fei Ai Za Zhi; 2010 Jul; 13(7):706-12. PubMed ID: 20673487
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and Prognostic Value of Serum Angiopoietin-Like Protein 2 in Patients with Non-Small Cell Lung Cancer.
Chen Y; Jiang H; Zhu L; Wang P; Liu S; Xiao X; Yu H; Dong W
Clin Lab; 2017 Jan; 63(1):59-65. PubMed ID: 28164488
[TBL] [Abstract][Full Text] [Related]
10. Serum anti-p53 antibodies in patients with lung cancer.
Mack U; Ukena D; Montenarh M; Sybrecht GW
Oncol Rep; 2000; 7(3):669-74. PubMed ID: 10767388
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer.
Zhang C; Ye L; Guan S; Jin S; Wang W; Sun S; Lee KH; Wei J; Liu B
Tumour Biol; 2014 Mar; 35(3):2047-51. PubMed ID: 24122232
[TBL] [Abstract][Full Text] [Related]
12. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.
Lam S; Boyle P; Healey GF; Maddison P; Peek L; Murray A; Chapman CJ; Allen J; Wood WC; Sewell HF; Robertson JF
Cancer Prev Res (Phila); 2011 Jul; 4(7):1126-34. PubMed ID: 21733826
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of serum miR-494 predicts poor prognosis in non-small cell lung cancer patients.
Zhang J; Wang T; Zhang Y; Wang H; Wu Y; Liu K; Pei C
Cancer Biomark; 2018; 21(4):763-768. PubMed ID: 29286916
[TBL] [Abstract][Full Text] [Related]
14. A specific autoantibody against a novel tumour-association antigen derived from human DNA-topoiomerase I is a potential biomarker for early diagnosis and favourable prognosis in patients with colorectal carcinoma.
Zhao F; Cao M; Jiang XH; Xie K; Ye SR; Yie SM
Biomarkers; 2020 Mar; 25(2):149-156. PubMed ID: 31922440
[No Abstract] [Full Text] [Related]
15. Elevated serum apolipoprotein E is associated with metastasis and poor prognosis of non-small cell lung cancer.
Luo J; Song J; Feng P; Wang Y; Long W; Liu M; Li L
Tumour Biol; 2016 Aug; 37(8):10715-21. PubMed ID: 26873483
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers.
Patel K; Farlow EC; Kim AW; Lee BS; Basu S; Coon JS; DeCresce D; Thimothy L; Walters KA; Fhied C; Chang C; Chen SH; Faber LP; Bonomi P; Liptay MJ; Borgia JA
Int J Cancer; 2011 Jul; 129(1):133-42. PubMed ID: 20824709
[TBL] [Abstract][Full Text] [Related]
17. Serum pleiotrophin could be an early indicator for diagnosis and prognosis of non-small cell lung cancer.
Du ZY; Shi MH; Ji CH; Yu Y
Asian Pac J Cancer Prev; 2015; 16(4):1421-5. PubMed ID: 25743809
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of plasma anti-TOPO48 autoantibody and blood survivin-expressing circulating cancer cells in patients with early stage endometrial carcinoma.
Jiang XH; Yao ZY; He X; Zhang JB; Xie K; Chen J; Cao M; Zhang J; Yie SM
Arch Gynecol Obstet; 2019 Jan; 299(1):229-237. PubMed ID: 30341503
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic significance of S100A2 and S100A6 levels in sera of patients with non-small cell lung cancer.
Wang T; Liang Y; Thakur A; Zhang S; Yang T; Chen T; Gao L; Chen M; Ren H
Tumour Biol; 2016 Feb; 37(2):2299-304. PubMed ID: 26361956
[TBL] [Abstract][Full Text] [Related]
20. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer.
Doseeva V; Colpitts T; Gao G; Woodcock J; Knezevic V
J Transl Med; 2015 Feb; 13():55. PubMed ID: 25880432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
